Raluca Verona

6.2k citations

61 papers · 3.2k indexed · 2 hit papers · h-index 26

Molecular Biology top 5%
Oncology top 2%
Genetics top 2%
Hematology top 1%
Immunology top 5%

Co-authors: Marisa S. Bartolomei Mellissa R.W. Mann Jacqueline A. Lees Leisha D. Nolen Jeffrey M. Trimarchi Richard M. Schultz Kenneth H. Moberg Adam S. Doherty
Topics: Multiple Myeloma Research and Treatments (32 papers)Monoclonal and Polyclonal Antibodies Research (27 papers)CAR-T cell therapy research (26 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Journal of Clinical Oncology
Partner nations: United States Netherlands Spain

In The Last Decade

Raluca Verona

59 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Ajai Chari, Monique C. Minnema et al. profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Raluca Verona

Since Specialization

Citations

This map shows the geographic impact of Raluca Verona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raluca Verona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raluca Verona more than expected).

Fields of papers citing papers by Raluca Verona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raluca Verona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raluca Verona. The network helps show where Raluca Verona may publish in the future.

Co-authorship network of co-authors of Raluca Verona

This figure shows the co-authorship network connecting the top 25 collaborators of Raluca Verona. A scholar is included among the top collaborators of Raluca Verona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raluca Verona. Raluca Verona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma 2024 ·Clinical Cancer Research ·Christie P.M. Verkleij,(unknown),Marloes E.C. Broekmans,Kristine A. Frerichs,(unknown),Carolien Duetz,(unknown),S. Rubina Baglio,Sheri Skerget,Rocío Montes de,Sonja Zweegman,Raluca Verona,Tuna Mutis,Niels W.C.J. van de Donk	25
2	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative reviewbreakdown → 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero,Niels W.C.J. van de Donk,Kodandaram Pillarisetti,Ingrid Cornax,Deeksha Vishwamitra,Kathleen Gray,Brandi Hilder,Jaszianne Tolbert,Thomas Renaud,Tara Masterson,Christoph Heuck,Colleen Kane,Raluca Verona,Philippe Moreau,Nizar J. Bahlis,Ajai Chari	51
3	Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study 2023 ·Cancer ·Ajay K. Nooka,Cesar Rodriguez,María‐Victoria Mateos,Salomon Manier,Katherine Chastain,Arnob Banerjee,Rachel Kobos,Keqin Qi,Raluca Verona,(unknown),Thomas G Martin,Niels W.C.J. van de Donk	36
4	Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma 2023 ·Cancer ·Thomas G Martin,María‐Victoria Mateos,Ajay K. Nooka,Arnob Banerjee,Rachel Kobos,Lixia Pei,Ming Qi,Raluca Verona,(unknown),Jennifer Smit,(unknown),Danielle Trancucci,Clarissa Uhlar,Niels W.C.J. van de Donk,Cesar Rodriguez	28
5	POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM) 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Niels W.C.J. van de Donk,Philippe Moreau,Alfred L. Garfall,Manisha Bhutani,Albert Oriol,Ajay K. Nooka,Thomas G. Martin,Laura Rosiñol,María‐Victoria Mateos,Nizar J. Bahlis,Rakesh Popat,Britta Besemer,Joaquín Martínez‐López,Amrita Krishnan,Michel Delforge,Danielle Trancucci,Raluca Verona,Tara Stephenson,Katherine Chastain,Surbhi Sidana	3
6	MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Salomon Manier,Ajay K. Nooka,Cesar Rodriguez,María‐Victoria Mateos,Katherine Chastain,Arnob Banerjee,Rachel Kobos,Keqin Qi,Raluca Verona,(unknown),Thomas G. Martin,Niels W.C.J. van de Donk	0
7	Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma 2022 ·Blood Advances ·Suzette Girgis,Shun Xin Wang Lin,Kodandaram Pillarisetti,Raluca Verona,Diego Vieyra,Tineke Casneuf,(unknown),Xin Miao,Yang Chen,Tara Stephenson,Arnob Banerjee,Brandi Hilder,Jeffery S. Russell,Jeffrey R. Infante,Yusri Elsayed,Jennifer Smit,Jenna D. Goldberg	30
8	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas 2022 ·Cancer Research Communications ·Anne W. J. Martens,(unknown),Renate de Boer,(unknown),An Ngo‐Huang,(unknown),Koen de Heer,Marcel Spaargaren,Christie P.M. Verkleij,Niels W.C.J. van de Donk,Homer Adams,Eric Eldering,Carel J.M. van Noesel,Raluca Verona,Arnon P. Kater	9
9	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma 2021 ·Blood Advances ·Christie P.M. Verkleij,Marloes E.C. Broekmans,Mark van Duin,Kristine A. Frerichs,Rowan Kuiper,(unknown),Martin Kaiser,Gareth J. Morgan,Amy Axel,Rengasamy Boominathan,Jocelyn Sendecki,Amy P. Wong,Raluca Verona,Pieter Sonneveld,Sonja Zweegman,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	117
10	Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma 2021 ·Blood ·Amrita Krishnan,Monique C. Minnema,Jesús G. Berdeja,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodríguez‐Otero,Elham Askari,María‐Victoria Mateos,Luciano J. Costa,Raluca Verona,Xuewen Ma,Suzette Girgis,Shiyi Yang,Brandi Hilder,Jeffery S. Russell,Jenna D. Goldberg,Ajai Chari	40
11	Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma 2020 ·Blood ·Christie P.M. Verkleij,Marloes E.C. Broekmans,Amy P. Wong,Sonja Zweegman,Raluca Verona,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	7
12	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy 2019 ·Lung Cancer ·Jeffrey C. Thompson,Wei‐Ting Hwang,Christiana Davis,Charuhas Deshpande,(unknown),Yashoda Rajpurohit,Vinod Krishna,(unknown),Raluca Verona,Matthew V. Lorenzi,Corey J. Langer,Steven Μ. Albelda	93
13	Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity 2017 ·Cancer Immunology Research ·Karla R. Wiehagen,Natasha Girgis,Douglas H. Yamada,Alexis K. Smith,Szeman Ruby Chan,Iqbal S. Grewal,Michael Quigley,Raluca Verona	135
14	TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1 2017 ·The Journal of Immunology ·(unknown),Olesya Chornoguz,Karen Leander,Fred M. Kaplan,Richard Carter,Michelle Kinder,Kurtis E. Bachman,Raluca Verona,(unknown),Vipul Bhargava,Sandra Santulli-Marotto	30
15	Maintenance of Paternal Methylation and Repression of the Imprinted H19 Gene Requires MBD3 2007 ·PLoS Genetics ·Kimberly J. Reese,Shu Lin,Raluca Verona,Richard M. Schultz,Marisa S. Bartolomei	65
16	X-tra! X-tra! News from the Mouse X Chromosome 2006 ·Developmental Biology ·Joanne L. Thorvaldsen,Raluca Verona,Marisa S. Bartolomei	35
17	Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics 2004 ·Genes & Development ·Aaron Aslanian,Phillip J. Iaquinta,Raluca Verona,Jacqueline A. Lees	145
18	Role of H19 3′ sequences in controlling H19 and Igf2 imprinting and expression 2004 ·Genomics ·Raluca Verona,Marisa S. Bartolomei	11
19	Disruption of Imprinted Gene Methylation and Expression in Cloned Preimplantation Stage Mouse Embryos1 2003 ·Biology of Reproduction ·Mellissa R.W. Mann,Young Gie Chung,Leisha D. Nolen,Raluca Verona,Keith E. Latham,Marisa S. Bartolomei	259
20	E2F Activity Is Regulated by Cell Cycle-Dependent Changes in Subcellular Localization 1997 ·Molecular and Cellular Biology ·Raluca Verona,Kenneth H. Moberg,Scott Estes,(unknown),(unknown),Jacqueline A. Lees	192

About Raluca Verona

Raluca Verona is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 61 papers that have together received 3.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (32 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and CAR-T cell therapy research (26 papers). The work is most often cited by research in Hematology (688 citations), Oncology (1.5k citations) and Molecular Biology (2.0k citations). Raluca Verona has collaborated with scholars based in United States, Netherlands and Spain. Frequent co-authors include Marisa S. Bartolomei, Mellissa R.W. Mann, Jacqueline A. Lees, Leisha D. Nolen, Jeffrey M. Trimarchi, Richard M. Schultz, Kenneth H. Moberg, Adam S. Doherty, Niels W.C.J. van de Donk and Catherine Rogers. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact